Angiogenesis as a therapeutic target
Top Cited Papers
- 14 December 2005
- journal article
- review article
- Published by Springer Nature in Nature
- Vol. 438 (7070) , 967-974
- https://doi.org/10.1038/nature04483
Abstract
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.Keywords
This publication has 89 references indexed in Scilit:
- Common mechanisms of nerve and blood vessel wiringNature, 2005
- Eph receptor signalling casts a wide net on cell behaviourNature Reviews Molecular Cell Biology, 2005
- Integrin signalling during tumour progressionNature Reviews Molecular Cell Biology, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Therapeutic stem and progenitor cell transplantation for organ vascularization and regenerationNature Medicine, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigen 1 1Edited by I. A. WilsonJournal of Molecular Biology, 1999
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993